Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed malignant solid tumor that involves an activated Ras/Raf/MAPK pathway, including the following:
• * Breast cancer
• * Prostate cancer
• * Colon cancer
• * Pancreatic cancer
• * Ovarian cancer
• * Non-small cell lung cancer
• * Melanoma
• * Papillary thyroid cancer
• Metastatic or unresectable disease
• Standard curative or palliative measures do not exist or are no longer effective
• No newly diagnosed, untreated, or uncontrolled brain metastases
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-2
• ANC ≥ 1,500/μL
• WBC ≥ 3,500/μL
• Platelet count ≥ 100,000/μL
• Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
• AST/ALT ≤ 2.5 times ULN (≤ 5 times ULN for tumor involvement of the liver)
• Creatinine ≤ 2 times ULN
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No neuropathy ≥ grade 1 with pain within the past 14 days
• No active infections
• No myocardial infarction within the past 6 months
• No NYHA class III or IV heart failure
• No uncontrolled angina
• No severe uncontrolled ventricular arrhythmias
• No evidence of acute ischemia or active conduction system abnormalities by ECG
• * Any ECG abnormality at screening must be documented by the investigator as not medically relevant
• No hypersensitivity to bortezomib, boron, or mannitol
• No serious medical or psychiatric illness likely to interfere with study participation
• PRIOR CONCURRENT THERAPY:
• Prior paclitaxel or bortezomib allowed
• At least 4 weeks since prior chemotherapy and/or radiotherapy
• More than 14 days since other prior investigational drugs
• No other concurrent investigational agents
• No other concurrent anticancer agents, including chemotherapy and biologic agents
• No concurrent recombinant interleukin-11 (Neumega®)